136 results for «100»

Filter By

136 results

Vascular robotics: Robocath unveils survey findings on users’ current expectations and future developments

15 May 2024

One-year results from the FUTURE-II trial

18 May 2021

A decade already passed from the first use of bioresorbable vascular scaffold in percutaneous coronary interventions. The first studies - by using surrogate endpoints - showed some superiority of BRS vs. metallic drug-eluting stent in terms of the so-called vascular restoration therapy with recovery of vasomotion...

One-year results from the FUTURE-II trial

Successful Stent-less Percutaneous Coronary Intervention of Chronic Total Occlusion by Ablation Devices in a Young Adult

04 Nov 2021

View this case with a 38-year-old male with effort angina and chronic total occlusion at the ostial segment of the left anterior descending artery.

Successful Stent-less Percutaneous Coronary Intervention of Chronic Total Occlusion by Ablation Devices in a Young Adult

DAPT-SHOCK-AMI trial: Cangrelor in cardiogenic shock

03 Sep 2025

Kalaivani Mahadevan and Fizzah Choudry provide their take on DAPT-SHOCK-MI presented by Zuzana Motovska at ESC Congress 2025 in Madrid.

Fizzah Choudry

Author

Fizzah Choudry
Kalaivani Mahadevan

Author

Kalaivani Mahadevan
DAPT-SHOCK-AMI trial: Cangrelor in cardiogenic shock

OPTIMIZE IDE: A randomized trial of a novel, ultra low profile fixed-wire DES

26 Oct 2020

At TCT Connect 2020, Late-Breaking Trial Session IV, the primary results of the OPTIMIZE IDE were presented by Dean J. Kereiakes. Daniele Giacoppo provides a summary of the trial.

Daniele Giacoppo

Author

Daniele Giacoppo
Live from TCT Connect 2020: The OPTIMIZE trial

Real-world outcomes with the PASCAL Platform in TR

03 Dec 2021

The PASCAL platform, comprising the PASCAL and PASCAL Ace implants, received its CE mark for TR in May 2020 and has been shown to be an effective and safe treatment option for patients with TR.3,4,6 Professor Jörg Hausleiter and Dr Mirjam Wild now describe their single-centre experience...

Real-world outcomes with the PASCAL Platform in TR

A large-scale, randomized trial of orbital atherectomy vs. conventional balloon angioplasty in severely calcified coronary arteries prior to DES implantation (ECLIPSE)

30 Oct 2024

Nicola Ryan provides her take on the ECLIPSE trial presented by Ajay J. Kirtane at TCT 2024 in Washington.

Nicola Ryan

Author

Nicola Ryan
A large-scale, randomized trial of orbital atherectomy vs. conventional balloon angioplasty in severely calcified coronary arteries prior to DES implantation (ECLIPSE)

GLORIOUS - Efficacy of restrictive versus liberal oxygenation or Exenatide in patients undergoing coronary artery bypass grafting or aortic valve replacement – a randomised clinical trial

21 Nov 2024

Edoardo Zancanaro provides his take on the GLORIOUS trial presented by Sebastian Wiberg at AHA 2024 in Chicago.

Edoardo Zancanaro

Author

Edoardo Zancanaro
GLORIOUS

Effective techniques for performing DCB angioplasty

16 Jan 2025

Drug-coated balloon (DCB) angioplasty has become a valuable alternative to drug-eluting stents in treating coronary artery disease. To achieve optimal outcomes, proper lesion preparation and techniques to minimise drug loss are crucial.

This article highlights key steps and best practices for performing DCB angioplasty, ensuring effective drug delivery and...

Valeria Paradies

Author

Valeria Paradies

Author

Gianluca Mincione
Effective techniques for performing DCB angioplasty

World Heart Day 2023: Reducing the burden of cardiovascular disease globally: beyond stents and balloons!

29 Sep 2023

Global burden of Cardiovascular Disease

Cardiovascular disease (CVD) remains the lead cause of mortality for men and women globally. Our world population in 2023 is 8 billion! Of these, around 620 million people are living with heart and circulatory diseases across the world. Each year around 60...

Vijay Kunadian

Author

Vijay Kunadian
World Heart Day 2023

Cardiac Dimensions raises $35 Million in Series D financing

05 Jan 2023

Landmark New England Journal of Medicine publication reports positive results from PROMISE II pivotal trial showing that LimFlow system saves most patients with end-stage peripheral artery disease from major amputation

30 Mar 2023

Positive echocardiography data from BioCardia phase III CardiAMP cell therapy heart failure trial presented at American College of Cardiology annual meeting

06 Mar 2023

EuroPCR 2024 – Built by and for its participants, more than ever before

29 Mar 2024

Over 11,000 participants from around the globe are once again expected at EuroPCR – a Course tailored for interventional cardiologists, cardiac surgeons, imaging specialists, radiologists, nurses, allied professionals and other practitioners, as well as researchers, innovators and industry representatives. They will be sharing their knowledge, skills and experience on...

EuroPCR 2024 – Built by and for its participants, more than ever before

The RELIEVE-HF study: is an atrial septal shunt beneficial in HFrEF?

07 Apr 2024

Charles Fauvel provides his take on the RELIEVE-HF study outcomes presented by Gregg W. Stone at ACC.24 in Atlanta.

Charles Fauvel

Author

Charles Fauvel
The RELIEVE-HF study: is an atrial septal shunt beneficial in HFrEF?

First-in-human data for Sensome clot-sensing guidewire used in ischemic stroke treatment demonstrate ability to automate clot characterization with no safety issues

05 Jun 2024

Amulet IDE: Amplatzer Amulet left atrial appendage occluder randomised controlled trial

31 Aug 2021

Luigi Biasco reports the best of Dj Lakkireddy (Overland Park, USA)'s presentation of the AMULET IDE trial at the Monday, August 30 Hot Line session of the ESC Congress 2021.

Luigi Biasco

Author

Luigi Biasco
ESC Congress 2021 - Amulet IDE: Amplatzer Amulet left atrial appendage occluder randomised controlled trial

The Lancet Commission to reduce global burden of cardiovascular disease in women by 2030

29 Aug 2021

Vijay Kunadian summarizes the key points of the LBT session of the ESC congress 2021 held on Sunday, 29 August focusing on the Lancet Commission to reduce the global burden of heart disease in women by 2030.

Vijay Kunadian

Author

Vijay Kunadian
ESC Congress 2021 - Global burden of cardiovascular disease in women; 20/20 vision for 2030: report of The Lancet commission

3-year Efficacy Outcomes From the Spyral Htn-on Med Pilot Study: Long Term Effect of Renal Denervation On Blood Pressure Reduction in Patients on Antihypertension Medications

22 Mar 2022

Ali Nazmi Calik provides his take on the long-term results of the SPYRAL HTN-ON MED trial which demonstrated the durable efficacy and safety of RDN in patients who are already on one to three antihypertensive drugs.

Author

Ali Nazmi Calik
3-year Efficacy Outcomes From the Spyral Htn-on Med Pilot Study: Long Term Effect of Renal Denervation On Blood Pressure Reduction in Patients on Antihypertension Medications

EuroPCR 2025 – One-month dual antiplatelet therapy followed by prasugrel monotherapy at a reduced dose: the 4D-ACS randomised trial

21 May 2025

Paris, France, 20-23 May 2025. The EuroPCR Course Directors have selected 3 major late-breaking trials that will be presented for the first time during the 2025 edition of EuroPCR. These trials were selected because of their design, results, and potential to impact practice, among them is the...

EuroPCR 2025 – One-month dual antiplatelet therapy followed by prasugrel monotherapy at a reduced dose: the 4D-ACS randomised trial
Didn’t find what you were looking for?